DekaBank Deutsche Girozentrale Trims Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

DekaBank Deutsche Girozentrale cut its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 20.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 263,122 shares of the medical equipment provider’s stock after selling 66,584 shares during the quarter. DekaBank Deutsche Girozentrale owned about 0.13% of Zimmer Biomet worth $31,901,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Stratos Wealth Partners LTD. increased its stake in Zimmer Biomet by 4.2% during the fourth quarter. Stratos Wealth Partners LTD. now owns 9,880 shares of the medical equipment provider’s stock worth $1,202,000 after acquiring an additional 402 shares during the last quarter. Stratos Wealth Advisors LLC acquired a new stake in Zimmer Biomet during the fourth quarter worth about $247,000. New York State Teachers Retirement System increased its stake in Zimmer Biomet by 2.6% during the fourth quarter. New York State Teachers Retirement System now owns 207,061 shares of the medical equipment provider’s stock worth $25,199,000 after acquiring an additional 5,239 shares during the last quarter. Matrix Asset Advisors Inc. NY increased its stake in Zimmer Biomet by 26.6% during the fourth quarter. Matrix Asset Advisors Inc. NY now owns 102,172 shares of the medical equipment provider’s stock worth $12,434,000 after acquiring an additional 21,459 shares during the last quarter. Finally, Boit C F David increased its stake in Zimmer Biomet by 187.5% during the fourth quarter. Boit C F David now owns 2,300 shares of the medical equipment provider’s stock worth $277,000 after acquiring an additional 1,500 shares during the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ZBH has been the subject of a number of recent research reports. Raymond James increased their target price on Zimmer Biomet from $133.00 to $137.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. JPMorgan Chase & Co. increased their target price on Zimmer Biomet from $115.00 to $125.00 and gave the company a “neutral” rating in a research note on Friday, February 9th. Citigroup increased their target price on Zimmer Biomet from $134.00 to $140.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. Evercore ISI increased their target price on Zimmer Biomet from $125.00 to $130.00 and gave the company an “in-line” rating in a research note on Thursday. Finally, TheStreet upgraded Zimmer Biomet from a “c” rating to a “b-” rating in a research note on Thursday, February 8th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and a consensus target price of $139.39.

Zimmer Biomet Stock Performance

Shares of NYSE ZBH opened at $127.33 on Monday. The company has a quick ratio of 0.78, a current ratio of 1.61 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $26.16 billion, a price-to-earnings ratio of 26.04, a PEG ratio of 2.34 and a beta of 1.01. The stock’s fifty day simple moving average is $126.50 and its 200 day simple moving average is $118.51. Zimmer Biomet Holdings, Inc. has a 52-week low of $102.00 and a 52-week high of $149.25.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.15 by $0.05. The business had revenue of $1.94 billion for the quarter, compared to analysts’ expectations of $1.93 billion. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The company’s quarterly revenue was up 6.3% on a year-over-year basis. During the same period in the previous year, the firm posted $1.88 EPS. As a group, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be given a $0.24 dividend. The ex-dividend date is Wednesday, March 27th. This represents a $0.96 annualized dividend and a dividend yield of 0.75%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 19.63%.

Insider Transactions at Zimmer Biomet

In other news, VP Chad F. Phipps sold 26,156 shares of the firm’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total value of $3,364,184.72. Following the completion of the sale, the vice president now owns 44,145 shares of the company’s stock, valued at $5,677,929.90. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.70% of the stock is currently owned by insiders.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.